Tumor stiffness shows up again and again in cancer diagnoses, yet its origins are not as straightforward as they are sometimes presented in research. Collagen accumulation and fibrosis are commonly linked, but those features alone do not explain how resistance to deformation (and consequently cancer growth) develops. In all likelihood, stiffness depends on how cancer cells organize and strengthen the extracellular matrix, which means it has to be studied as a mechanical property of the tumor microenvironment, not just a compositional one.
Recent work from Sapporo Medical University, published in the International Journal of Molecular Sciences, takes this approach by combining large-scale transcriptomic analysis with direct mechanical testing of three-dimensional cell models. Central to the study is the use of micro-compression testing, performed with a CellScale MicroTester (AKA MicroSquisher), to quantify how cancer-associated fibroblasts contribute to tumor stiffness through collagen organization.
As you can see below, rather than inferring mechanics indirectly, the authors measure stiffness directly, allowing molecular and cellular observations to be connected to physical function.
A Pan-Cancer Link Between AEBP1 and Extracellular Matrix Remodeling
The study begins with a broad question: is there a conserved molecular program associated with collagen organization and tissue stiffening across cancers?
To answer this, the authors analyzed RNA sequencing data from The Cancer Genome Atlas across more than thirty tumor types. One gene stood out. Expression of AEBP1 (Adipocyte enhancer-binding protein 1) consistently tracked with gene sets involved in collagen metabolism, extracellular matrix organization, and structural matrix binding across most solid tumors.
Interestingly, AEBP1 expression was not limited to just one or two cancer types. It appeared repeatedly in many tumors with substantial stromal components, which suggests that AEBP1 is part of a common extracellular matrix remodeling program (rather than a cancer-specific anomaly).
Figure 1. Pan-cancer gene ontology analysis showing that genes correlated with AEBP1 expression are enriched in collagen metabolic processes and extracellular matrix organization across most solid tumors. Image reproduced from Sekiguchi et al., International Journal of Molecular Sciences, 2025, open access under CC BY 4.0.
So, there is correlation with AEBP1 expression, but what about causation? The next logical step is to identify which cells within the tumor are responsible for expressing AEBP1 and producing collagen.
Cancer-Associated Fibroblasts as a Source of Tumor Stiffness
The authors next worked with single-cell RNA sequencing data from pancreatic cancer. Pancreatic tumors are often used in this context because their stroma is dense, collagen rich, and mechanically resistant, sometimes to a degree that complicates treatment.
When the data were broken down by cell type, AEBP1 did not appear evenly across the tumor. Most of the AEBP1 signal came from cancer-associated fibroblasts rather than other tumor cell types. In those same fibroblast populations, collagen-related genes like COL1A1 and COL3A1 were also prominent. The cells could be identified as CAFs based on the presence of markers such as ACTA2, FAP, and PDGFRB.
Other tumor-associated cells showed little AEBP1 signal by comparison. There was also no clear separation where only one fibroblast group expressed it. Instead, AEBP1 showed up across multiple CAF populations. That pattern is consistent with a role tied to fibroblast-driven matrix organization rather than a feature of a single specialized subtype.
Figure 4. Single-cell RNA sequencing analysis of pancreatic cancer tissue showing preferential expression of AEBP1 and collagen genes in cancer-associated fibroblasts across multiple CAF subtypes. Image reproduced from Sekiguchi et al., International Journal of Molecular Sciences, 2025, open access under CC BY 4.0.
These observations point to a straightforward hypothesis: if AEBP1-expressing fibroblasts are major producers and organizers of collagen, then altering AEBP1 expression should change the mechanical properties of fibroblast-generated tissue.
Mechanical Testing of CAF-Derived 3D Spheroids
Testing that hypothesis requires a model system where stiffness can be measured independently of gross tissue architecture. For this, the authors used three-dimensional spheroids formed from cancer-associated fibroblasts. These spheroids allow fibroblasts to self-organize and deposit extracellular matrix in a manner that more closely resembles in vivo stroma than flat cultures.
After knocking down AEBP1 using siRNA, fibroblast spheroids were subjected to controlled compression testing using the MicroTester from CellScale. This approach applies precisely defined forces while measuring deformation, providing a direct readout of mechanical stiffness.
The results clearly showed that spheroids formed from AEBP1-depleted fibroblasts were significantly softer than control spheroids. At the same time, spheroid size and overall morphology remained largely unchanged. The difference was mechanical, not structural.
Figure 6. Mechanical compression testing of cancer-associated fibroblast-derived 3D spheroids demonstrating reduced stiffness following AEBP1 knockdown, without changes in spheroid size or morphology. Compression measurements were performed using micro-compression testing with the MicroTester. Image reproduced from Sekiguchi et al., International Journal of Molecular Sciences, 2025, open access under CC BY 4.0.
This distinction matters. This shows that tumor stiffness can be tuned through extracellular matrix reinforcement (rather than changes in tissue mass or geometry). This reinforces the idea that stiffness is an independent and measurable phenotype.
Quantifying Tumor Microenvironment Mechanics with the MicroTester
The MicroTester plays a central role in this work by enabling direct measurement of stiffness in intact, three-dimensional biological samples. Unlike indirect proxies or qualitative observations, micro-compression testing captures how tissues resist deformation under load.
In this study, the MicroTester allowed the authors to decouple mechanical behavior from visual appearance. As you can see in the figure above, two spheroids can look nearly identical under a microscope while exhibiting markedly different stiffness profiles when compressed. That distinction is critical when studying fibrotic tumors, where immune cell infiltration and drug transport are strongly influenced by mechanical resistance rather than morphology alone.
By integrating mechanical testing into a molecular and cellular workflow, the authors demonstrate how biomechanical measurements can clarify the functional consequences of gene expression changes in the tumor microenvironment.
Related Work from the Same Research Team
This study builds on a broader body of cancer research from the same team at Sapporo Medical University in Japan.
In earlier work examining ovarian carcinoma, the authors investigated how regulators of fatty acid metabolism influence tumor progression using spheroid-based culture systems. That study (also using the MicroTester (“MicroSquisher”)) showed how metabolic programs intersect with stromal organization and tumor behavior.
The integration of mechanical testing in the current work extends this framework by directly quantifying how fibroblast-driven extracellular matrix remodeling alters tumor stiffness.
Why Tumor Stiffness Matters
Stiffness in tumors is not just something that develops alongside cancer growth. A rigid extracellular matrix can restrict immune cell movement, disrupt signaling between cells, and contribute to poor therapeutic response. For these reasons, stiffness is now being viewed less as a side effect and more as a property that may be altered to improve treatment outcomes.
This study identifies AEBP1 as a conserved regulator linking fibroblast activity, collagen organization, and tissue mechanics across cancers. Just as importantly, it illustrates why measuring stiffness directly is necessary. Without mechanical testing, changes in extracellular matrix organization remain difficult to interpret in functional terms.
Connecting Molecular Programs to Mechanical Function
This study brings together transcriptomic analysis and mechanical testing to examine the same system from different angles. While gene expression provides clues about underlying biological activity, mechanical measurements are needed to determine how those signals manifest as changes in tissue stiffness.
The results emphasize a broader point for cancer mechanobiology. To understand how the tumor microenvironment shapes disease progression, stiffness must be treated as a measurable property, not an inferred one.
Read the Full Publication
About the CellScale MicroTester
The CellScale MicroTester is used to measure the mechanical response of soft biological samples under compression. It is commonly applied to three-dimensional cell cultures, tissue explants, and other deformable materials where small forces and subtle changes in stiffness matter. In studies like this one, the system makes it possible to relate changes in gene expression or matrix organization to measurable differences in how a sample deforms under load.
